Open AccessDeterminants and Changes Associated with Aldosterone Breakthrough after Angiotensin II Receptor Blockade in Patients with Type 2 Diabetes with Overt Nephropathy
Author(s) -
Olivier Moranne,
George L. Bakris,
C. Fafin,
Guillaume Favrè,
Christian Pradier,
Vincent Esnault
Publication year - 2013
Publication title -
clinical journal of the american society of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.755
H-Index - 151
eISSN - 1555-905X
pISSN - 1555-9041
DOI - 10.2215/cjn.06960712
Subject(s) - aldosterone , medicine , endocrinology , losartan , telmisartan , renin–angiotensin system , angiotensin ii , nephropathy , angiotensin ii receptor type 1 , diabetes mellitus , losartan potassium , diabetic nephropathy , angiotensin receptor , plasma renin activity , proteinuria , kidney , blood pressure
Inhibition of the renin-angiotensin-aldosterone system decreases proteinuria and slows estimated GFR decline in patients with type 2 diabetes mellitus with overt nephropathy. Serum aldosterone levels may increase during renin-angiotensin-aldosterone system blockade. The determinants and consequences of this aldosterone breakthrough remain unknown.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom